Invitae joins NIH-sponsored study aimed at improving understanding of the links between genes and cancer, heart disease and other conditions
SAN FRANCISCO, April 8, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, has joined eMERGE Network, a nationwide effort organized and funded by the National Human Genome Research Institute (NHGRI) that connects genetic data and electronic medical record (EMR) systems to advance the use of genetics in healthcare. As a new clinical affiliate, Invitae will provide genetic testing for a study of up to 25,000 patients to evaluate the impact of population screening.
"Our own research has shown that people can harbor a genetic change that could put them at increased risk for conditions like cancer and heart disease. The eMERGE study is part of the work conducted by the NHGRI to improve understanding of these rates in diverse populations, with an emphasis on underrepresented minorities, and identify best practices for population screening," said Robert Nussbaum, M.D., chief medical officer at Invitae. "We're proud to be participating in this important effort, through which we hope to not only help provide information that study participants can use to improve their health but also contribute important findings that may improve healthcare for all."
Participants enrolled in the study conducted through the effort will receive genetic testing through Invitae to identify genetic changes linked to conditions such as coronary artery disease, hereditary breast and ovarian cancer, and Lynch syndrome, along with access to follow-up testing for family members. In addition to testing, Invitae will provide clinical resources for participants in the study, including the opportunity to interact with Gia, Invitae's advanced clinical chatbot, to learn more about the genetic testing process and what their results mean.
Using findings about genetic changes and information from EMRs, study researchers will work to deepen understanding of the connections between genetics and health and to develop ways to put that knowledge into practice to help improve patient care. Importantly, participating study sites are particularly focused on including diverse populations, such as underrepresented minority populations, underserved populations, or populations who experience poorer medical outcomes.
About eMERGE Network
Safe Harbor Statement
Source: Invitae Corporation
View original content to download multimedia:http://www.prnewswire.com/news-releases/invitae-joins-nih-sponsored-study-aimed-at-improving-understanding-of-the-links-between-genes-and-cancer-heart-disease-and-other-conditions-301264664.html
SOURCE Invitae Corporation
Company Codes: NYSE:NVTA